The easy-to-use Transderm Ionto DEP system from Mattioli Engineering Corp. (Arlington, Va.) is a patented, FDA-cleared device that experts say vastly outperforms competitors. From standard sera or drugs, including lidocaine, hyaluronic acid, Type A Botulinum toxin, steroids or vitamins, to a physician’s own proprietary formulations and regenerative therapies like growth factors and PRP, Transderm implants them all using DermoElectroPoration (DEP).
Employing a controlled current, DEP technology even manages skin permeability well enough to deliver compounds with molecules that, in the past, were too large to implant in such a manner. Formerly classified as Class III, the Transderm DEP system is now a Class II medical device, removing many limits to its use and marketing that may have previously hindered the growth of this remarkable device.
According to Frank Carletti, president and CEO of Venus Derm Aesthetic Center MedSpa and Venus Derm Labs (Tampa, Fla.), this device is second to none. Venus Derm manufactures proprietary sera for a variety of applications, all of which are easily delivered with the Transderm DEP system. These formulations are used in-house by their own medspa, as well as sold to other clinics looking for the same outstanding results.
“Compared to similar devices we’ve tried – and we’ve tried them all – Transderm DEP not only does a better job, it can deliver 15 cc of product within 30 minutes, which is easily three times greater volume than anything else,” he stated. “And there is minimal waste, especially compared to other devices, so you know you are delivering therapeutic products effectively. There is literally nothing else like this device out there.”
Transderm DEP does not cause electrolytic modification of product or drug pH, and there is no need to use a carrying gel or pre-charge the compound before implantation. And unlike other systems, delivery is homogeneous in the treatment area, with real-time control of the amount of product delivered using real-time skin impedance feedback to properly manage speedy delivery.
The real beneficiary is the patient, according to Mr. Carletti. Iontophoresis with Transderm DEP is comfortable for patients and causes no trauma to the skin. There is no irritation or inflammation that would limit future electrode placement.
“This system is truly next-generation, and the results we see are excellent,” he reported. “The combination of our sera and Transderm DEP gives patients instant results, as well as the long-term benefits associated with use of the products. We have many protocols, but most are close to six weekly sessions, followed by monthly maintenance, which patients are more than happy to do.”
Applications for Transderm DEP are as numerous as the compounds it can deliver. Any situation where transdermal delivery of compounds would be advantageous is possible, including mesotherapy or botulinum toxin injections, implanting product to improve stretch marks or anesthesia during labial rejuvenation, pain management, and sports medicine. Its classic use in aesthetic medicine is with hyaluronic acid and growth factors for facial rejuvenation.
“Physicians are sometimes slow to change, but the utility of Transderm DEP makes it extremely attractive,” Mr. Carletti noted. “Once you’ve seen what it can do, why would you do things the old way when this works so well and has so many possible applications?”